Onconase ranpirnase: Phase II results; Phase III

ACEL reported in the Journal of Clinical Oncology 1- and 2-year survival rates of 34.3% and 21.6%, respectively, in an open-label Phase II trial of Onconase in 105 patients with unresectable malignant...